Citations

Clear

13603 citation(s) found for "_, _".

Trends in Gastric Cancer Mortality in the US: A Population-Based Analysis, 1999-2023
Khan, Saba , Shahid, Hafsa , Fatima, Noor , Khawar, Muneeb , Waqas, Muhammad , Rehan, Aimen, Saif, Maha , Qadeer, Abdul , Iqbal, Javed

Mayo Clinic

No container title available | May 13, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6327806/v1 Get It

Abstract Purpose Gastric cancer is a leading cause of mortality worldwide, with pronounced variations in outcomes across populations. This study investigates U.S. trends in age-adjusted mortality rates (AAMRs) for gastric cancer from 1999 to 2023, examining differences by sex, race, region, and urbanization to uncover critical patterns and inequities. Methods Data were extracted from the CDC WONDER database using ICD-10 code C16 to identify gastric cancer-related deaths in adults aged 25 and older. AAMRs per 1,000,000 population were calculated and stratified by year, sex, race/ethnicity, geographic region, and urban-rural classification. Trends were analyzed using Joinpoint regression to determine annual percentage changes (APC) and 95% confidence intervals (CI). Statistical significance was set at p < 0.05. Results From 1999 to 2023, there were 312,300 gastric cancer deaths (185,391 men, 126,909 women). Overall, AAMRs declined consistently, with APCs of -3.4 for the period 1999 to 2007, -2.2 for 2007 to 2018, and − 1.2 for 2018 to 2023. Men showed a more pronounced decline, with APCs of -3.6 for 1999 to 2009 and − 2.2 for 2009 to 2023, compared to women, who had APCs of -3.1 for 1999 to 2008, -1.9 for 2008 to 2018, and − 0.8 for 2018 to 2023. Non-Hispanic Black populations experienced a decline in AAMR with an APC of -3.3 for 1999 to 2020, while Hispanic/Latino and Asian/Pacific Islander populations showed declines with APCs of -2.8 for 1999 to 2011 and − 3.8 for 1999 to 2020, respectively. Metropolitan areas saw AAMR reductions with APCs of -3.3 for 1999 to 2008 and − 2.2 for 2008 to 2020, while non-metropolitan areas had larger initial declines with an APC of -3.6 for 1999 to 2006 but slower decreases with an APC of -2.0 for 2006 to 2020. Geographically, the Northeast had the highest AAMR (62.9), followed by the West (61.7), South (57.4), and Midwest (50.9). Hawaii recorded the highest state-level AAMR (96.5), while Wyoming had the lowest (36.6). States in the top 90th percentile included Alaska, California, and New York, whereas Utah, Idaho, and Iowa were among the lowest. Conclusion Gastric cancer mortality in the U.S. has declined over the past two decades, but the pace of reduction has slowed in recent years. Significant disparities persist across sex, racial, and geographic groups, underscoring the need for targeted interventions to address these inequities and improve outcomes in vulnerable populations.
Relationship between use of anti‐platelet agents, oral anti‐coagulants, and Aβ burden with cerebral microhemorrhages in cognitively asymptomatic adults
Gay, Marcus , Baldaranov, Dobri , Jack, Clifford R. , Aisen, Paul, Jack, Clifford R , Donohue, Michael , Sperling, Reisa Anne , Rafii, Michael S.

Mayo Clinic

Alzheimer's & Dementia | May 13, 2025 | Volume: 21 | Issue: 5 | Pages: No page available

10.1002/alz.70167 | PMID 40356042 Get It

AbstractINTRODUCTIONCerebral microhemorrhages (CMHs) are detectable by magnetic resonance imaging (MRI). CMHs in deep brain regions are linked to hypertensive vasculopathy, while those in lobar regions with amyloid beta (Aβ) deposition in blood vessels. This study aims to determine the association between anti‐thrombotic treatment and CMH prevalence among cognitively asymptomatic adults, and to assess the role of Aβ markers, apolipoprotein E (APOE) ε4 carrier status, and cardiovascular risk factors in CMH development.METHODSUsing baseline data from the Anti‐Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) studies, we examined CMH presence via 3T MRI, along with medication use, APOE ε4 carrier status, medical history, and blood pressure.RESULTSOur analysis showed a significantly higher prevalence of CMHs in the A4 cohort (17.3%) compared to the LEARN cohort (2.6%).DISCUSSIONFactors such as male sex, age, Aβ markers, and APOE ε4 status were significantly associated with higher CMH prevalence in the A4 cohort. However, anti‐thrombotic treatment did not show association with overall CMHs.Highlights Male sex, age > 75, amyloid beta (Aβ) burden, and apolipoprotein E (APOE) ε4 homozygosity are significantly associated with higher prevalence of CMHs (cerebral microhemorrhages) in a cohort of cognitively asymptomatic individuals. Male sex, age > 75, Aβ burden, and APOE ε4 homozygosity are significantly associated with higher prevalence of lobar CMHs in a cohort of cognitively asymptomatic individuals. Anti‐platelet or anti‐coagulant usage were not associated with an increased prevalence of CMHs in either brain location or overall, in a cohort of cognitively asymptomatic individuals. History of a lipid disorder is associated with a higher prevalence of lobar CMHs in a cohort of cognitively asymptomatic individuals.
Epilepsy at Precision Medicine Crossroads—Disease Modification, Presymptomatic Treatment, and Early Screening
Brunklaus, Andreas , Lal, Dennis , Brunklaus, Andreas , Ivaniuk, Alina , Pestana‐Knight, Elia

Mayo Clinic

JAMA Neurology | May 12, 2025 | Volume: 82 | Issue: 10 | Pages: 975

10.1001/jamaneurol.2025.1179 | PMID 40354070 Get It

This Viewpoint describes the benefits and challenges of integrating genomic information with disease-modifying therapies for epilepsy.
The formal EU-US Meniscus Rehabilitation 2024 Consensus. An ESSKA-AOSSM-AASPT Initiative. Part I –Rehabilitation Management After Meniscus Surgery (Meniscectomy, Repair, Reconstruction)
Pujol, Nicolas , Giordano, Airelle O., Beaufils, Philippe , Monllau, Juan Carlos , Arhos, Elanna K. , Villa, Francesco Della, Goodloe, J. Brett , Irrgang, James J., Klosterman, Emma L. , Manske, Robert C. , Melick, Nicky van , Monson, Jill K. , Paterno, Mark V. , Piontek, Tomasz , Schmitt, Laura C. , Benjamin, C., Irrgang, James J. , Rambaud, Alexandre , Irrgang, James J , Arhos, Elanna K , Rambaud, Alexandre , Pujol, Nicolas , Giordano, Airelle O., Wong, Stephanie E. , Becker, Roland, Villa, Francesco Della, Klugarová, Jitka , Królikowska, Aleksandra , Krych, Aaron J. , LaPrade, Robert F. , Ostojić, Marko , Piontek, Tomasz , Perelli, Simone , Rambaud, Alexandre, Robinson, James Theodore , Senorski, Eric Hamrin , Snæbjörnsson, Thorkell , Tagliero, Adam J. , Prill, Robert

Mayo Clinic

International Journal of Sports Physical Therapy | May 12, 2025 | Volume: 20 | Issue: 6 | Pages: No page available

10.26603/001c.137095 Get It

Purpose The aim of part-one of this EU-US consensus was to combine literature research and expertise to provide recommendations for the usage of rehabilitation (including physical therapy) of patients undergoing surgical treatment for degenerative meniscus lesions or acute meniscus tears (including meniscectomy, repair, or reconstruction). Prevention programs, non-operative treatment of acute tears and degenerative lesions, return to sports and patient-reported outcome measures (PROMS) will be presented in a part-II article. Methods This consensus followed ESSKA “formal consensus” methodology. For this combined ESSKA (European Society for Sports Traumatology and Arthroscopy), AOSSM (American Orthopedic Society for Sports Medicine), ASSPT (American Academy of Sports Physical Therapy) initiative, 67 experts (26 in the steering group and 41 in the rating group) from 14 countries (USA and 13 European countries) including orthopedic surgeons, sports medicine doctors and physiotherapists were involved. Steering group members established guiding questions, searched the literature, proposed statements. Rating group members assessed the statements according to a Likert scale and provided grades of recommendations reaching final agreement about rehabilitation of the knee after meniscus surgery. Final documents were then assessed by a peer review group to adress the geographical adaptability. Results The overall level of evidence of the literature was low. Of the 19 questions (leading to 29 statements), one received a grade A of recommendation, two a grade B, nine a grade C and 17 a Grade D. Nevertheless, the mean median rating of all questions was 8.2/9 (9 being the highest rating on a scale of 1-9) and the global mean rating was 8.4+/-0.2, indicating a high agreement. Rehabilitation depends on the type of lesion, the treatment performed and is the same after medial or lateral meniscus surgery. Rehabilitation after meniscectomy should follow a criterion-based rehabilitation protocol, based on milestones rather than a time-based protocol. After meniscus repair and reconstruction, rehabilitation should be progressed according to both time and criterion-based milestones. Conclusion Rehabilitation after meniscus surgery is a debated topic that may influence surgical outcomes if not optimally performed. This international formal consensus established clear, updated, and structured recommendations for both surgeons and physiotherapists treating patients after meniscus surgery. Level of Evidence I, Consensus.
The formal EU‐US Meniscus Rehabilitation 2024 Consensus: An ESSKA‐AOSSM‐AASPT initiative. Part I—Rehabilitation management after meniscus surgery (meniscectomy, repair and reconstruction)
Pujol, Nicolas , Giordano, Airelle O., Beaufils, Philippe , Monllau, Juan Carlos , Arhos, Elanna K. , Villa, Francesco Della, Goodloe, J. Brett , Irrgang, James J., Klosterman, Emma L. , Manske, Robert C. , Melick, Nicky van , Monson, Jill K. , Paterno, Mark V. , Piontek, Tomasz , Rambaud, Alexandre , Schmitt, Laura C. , Benjamin, C. , Irrgang, James J. , Irrgang, James J , Arhos, Elanna K , Rambaud, Alexandre , Pujol, Nicolas , Wong, Stephanie E. , Becker, Roland, Villa, Francesco Della, Klugarová, Jitka , Królikowska, Aleksandra , Krych, Aaron J. , LaPrade, Robert F. , Ostojić, Marko , Piontek, Tomasz , Perelli, Simone , Robinson, James Theodore , Senorski, Eric Hamrin , Snæbjörnsson, Thorkell , Tagliero, Adam J. , Benjamin, C. , Prill, Robert

Mayo Clinic

Knee Surgery, Sports Traumatology, Arthroscopy | May 12, 2025 | Volume: 33 | Issue: 8 | Pages: 3002-3013

10.1002/ksa.12674 | PMID 40353298 Get It

Abstract Purpose The aim of part one of this EU‐US consensus was to combine literature research and expertise to provide recommendations for the usage of rehabilitation (including physical therapy) of patients undergoing surgical treatment for degenerative meniscus lesions or acute meniscus tears (including meniscectomy, repair, or reconstruction). Prevention programmes, non‐operative treatment of acute tears and degenerative lesions, return to sports and patient‐reported outcome measures will be presented in a part II article. Methods This consensus followed the European Society for Sports Traumatology and Arthroscopy (ESSKA)'s ‘formal consensus’ methodology. For this combined ESSKA, American Orthopedic Society for Sports Medicine and American Academy of Sports Physical Therapy initiative, 67 experts (26 in the steering group and 41 in the rating group) from 14 countries (US and 13 European countries), including orthopaedic surgeons, sports medicine doctors and physiotherapists were involved. Steering group members established guiding questions, searched the literature and proposed statements. Rating group members assessed the statements according to a Likert scale and provided grades of recommendations, reaching a final agreement about rehabilitation of the knee after meniscus surgery. Final documents were then assessed by a peer review group to address the geographical adaptability. Results The overall level of evidence in the literature was low. Of the 19 questions (leading to 29 statements), 1 received a Grade A of recommendation, 2 a Grade B, 9 a Grade C and 17 a Grade D. Nevertheless, the mean median rating of all questions was 8.2/9 (9 being the highest rating on a scale of 1–9). The global mean rating was 8.4 ± 0.2, indicating a high agreement. Rehabilitation depends on the type of lesion, the treatment performed and is the same after medial or lateral meniscus surgery. Rehabilitation after meniscectomy should follow a criterion‐based rehabilitation protocol, based on milestones rather than a time‐based protocol. After meniscus repair and reconstruction, rehabilitation should be progressed according to both time and criterion‐based milestones. Conclusion Rehabilitation after meniscus surgery is a debated topic that may influence surgical outcomes if not optimally performed. This international formal consensus established clear, updated and structured recommendations for both surgeons and physiotherapists treating patients after meniscus surgery. Level of Evidence Level I, consensus.
Antigen-specific Immunoprofiling in a Patient With Eisenmenger Syndrome, Treated Tuberculosis, and Atypical Non-tubercular Mycobacteria (NTM) Isolation Prior to Bilateral Lung Transplant
Lynn-Green, E., Pathakumari, Balaji , Keulen, Virginia P. Van , Peikert, Tobias, Pennington, Kelly M. , Escalante, Patricio , Gutierrez, L.E.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7894-A7894

10.1164/ajrccm.2025.211.abstracts.a7894 Get It

Abstract Non-tubercular mycobacteria (NTM) present a serious challenge in managing lung transplant candidates and recipients. Pretransplant NTM isolation has been associated with post-transplant NTM infection and significantly increased mortality risk. Strategies for managing pre-transplant NTM isolation vary widely in clinical practice. We present a 35-year-old lung transplant candidate from a tuberculosis-endemic country with severe pulmonary hypertension and Eisenmenger Syndrome due to unrepaired atrial septal defect, who underwent bilateral lung transplantation. Two years prior to transplant, she was successfully treated for pulmonary tuberculosis with six months of an unknown regimen in her home country. After moving to the U.S., she received M. tuberculosis (MTB) clearance from her state tuberculosis board, with three negative sputum samples six months prior to transplant. During her transplant evaluation, multi-drug-resistant M. fortuitum complex was isolated from one mycobacterial sputum culture. There was no clinical or radiographic evidence of active lung infection, and no targeted therapies were added. Standard peri-transplant antibiotics (vancomycin, cefepime, and caspofungin) were given. The patient received basilixamab for induction immunosuppression, and tacrolimus, mycophenolate mofetil, and prednisone for maintenance immunosuppression. Explant pathology showed necrotizing granuloma in the right upper lobe with acid-fast bacilli (AFB). The differential diagnosis included non-viable MTB, viable MTB despite prior clearance, or M. fortuitum. Three bronchoscopy washings were obtained in the first week post-transplant and returned negative for MTB by PCR, AFB stain, and culture. In collaboration with the Mycobacteriology laboratory, broad-range PCR testing was performed on the formalin-fixed paraffin-embedded samples from the explanted right lung, which was positive for MTB complex DNA. In total, the patient completed six sputum samples within the year pre-transplant and six respiratory samples within a month post-transplant, all of which returned negative for MTB by PCR, AFB stain, and culture. Blood flow cytometric (FC) immunoprofiling with mycobacterial antigens and controls was conducted (Escalante et al. 2015). The patient's FC antigen-specific activated T-cell profiling was consistent with a reduced risk of latent TB infection (FC CD4+ CD25+CD134+ T-cells (RD1-peptides-nil) = 0.19%). T-cell reactivity to MTB300 and PPD antigens suggested prior MTB, NTM, and/or BCG vaccination exposures. She progressed well without any preventive therapy for LTBI. FC immunoprofiling one year after transplantation showed similar results. She continues to have good pulmonary function and quality of life in her second-year post-transplant without evidence of NTM or MTB infection. Escalante P, et al. Combinatorial Immunoprofiling in Latent Tuberculosis Infection. Am J Respir Crit Care Med. 2015;192(5):605-17. PMCID: PMC4595688.
Triple Threat: Myositis, Myocarditis, and Myasthenia Gravis Overlap Syndrome Triggered by Immune Checkpoint Inhibitors in Metastatic Melanoma
Li, Song , Sen, Adrish , Rajesh, S.T., Chen, Jing , Sen, A.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7535-A7535

10.1164/ajrccm.2025.211.abstracts.a7535 Get It

Abstract Immune checkpoint inhibitor (ICI) therapy has significantly advanced cancer treatment, particularly for metastatic melanoma, but it is associated with severe, life-threatening adverse effects. A rare but critical complication is the overlap syndrome of Myositis, Myocarditis, and Myasthenia Gravis (MMM), affecting approximately 0.21% of ICI-treated solid tumor patients with an in-hospital mortality rate of up to 60%. Early recognition and management are crucial for improving outcomes. Case Presentation: A 76-year-old male with metastatic melanoma, coronary artery disease, ischemic cardiomyopathy (EF 35%), chronic kidney disease, diabetes, and chronic respiratory failure (baseline oxygen requirement of 2L) presented two weeks after starting Nivolumab and Relatlimab. He developed worsening exertional dyspnea, orthopnea, diplopia, dysarthria, and progressive proximal muscle weakness. On presentation, he was hemodynamically stable, with elevated troponin T (1241 ng/L) and NT-proBNP (2698 pg/mL). Initial investigations, including EKG and chest X-ray, were unremarkable with no thymoma. Left heart catheterization revealed severe multivessel coronary artery disease but no treatable lesions. He was noted to have fatigable ptosis and he subsequently developed bulbar symptoms, including hypophonia and dysphagia. A diagnosis of Myasthenia Gravis was suspected. Further evaluation showed respiratory muscle weakness (NIF -12 cm H2O, vital capacity 2L, mild hypercarbia on ABG) and progressive weakness, leading to intubation. Elevated creatine kinase (1527 U/L), persistent troponin elevation, and global hypokinesis on repeat echocardiography pointed to a likely diagnosis of myocarditis/myositis. Electromyography revealed neuropathy without acute findings, and serological testing for acetylcholine receptor antibodies, HMG-CoA reductase antibodies, and myositis was negative. ICI-induced MMM was diagnosed, and the patient was treated with methylprednisolone, IVIG, pyridostigmine, and ICI discontinuation. Despite plasmapheresis, his condition deteriorated. He developed septic shock from multiple infections (E-Coli bacteremia, Stenotrophomonas pneumonia) and progressed to cardiogenic shock, requiring vasopressors. Subsequent imaging revealed pneumoperitoneum concerning bowel perforation, but further diagnostic workup was declined by the family. Comfort care was initiated, and the patient passed away. Discussion: ICI use has grown rapidly, with agents like Nivolumab expanding treatment options for metastatic melanoma. However, MMM, a rare but severe complication, demands prompt recognition. Presentation often occurs within 21 days of ICI initiation, and patients may display elevated CPK and stable or rising troponin levels. Myasthenia gravis within MMM can cause rapid respiratory failure, with significant morbidity. Management includes corticosteroids, IVIG and immediate ICI discontinuation. Treatment should begin without waiting for confirmatory tests, given the syndrome's high mortality. Early, multidisciplinary intervention is essential in managing this fatal condition effectively.
A Tale of Two (Rare) Illnesses: Fibrosing Mediastinitis, Initially Diagnosed as IgG4-related Disease
Kolasa, Kathryn M. , Egan, Aoife M. , Kolasa, K.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A6681-A6681

10.1164/ajrccm.2025.211.abstracts.a6681 Get It

Abstract Fibrosing mediastinitis is an infiltrative disease which may develop secondary to a variety of causes, including autoimmune, infectious, and malignant processes. Here, we present a case of fibrosing mediastinitis, with initial concerns for IgG4-related disease. A 36-year-old man presented to his primary provider with three months of intermittent dyspnea. CT chest was significant for a large, infiltrative mediastinal and left hilar mass with calcifications and involvement of the left upper and lower lobe bronchi, lingular bronchus, and left main pulmonary artery. Subsequent autoimmune and fungal studies were negative. The patient underwent bronchoscopy, with biopsy of a lymph node at station 11L showing increased IgG4 on immunostain (30 cells/hpf), though IgG immunostaining was not completed for comparison. Despite initial concerns for fibrosing mediastinitis, the patient was diagnosed with IgG4-related disease and initiated on rituximab and mycophenolate. Notably, the patient's serum IgG4 concentrations were consistently within normal limits before and after initiation of rituximab. The patient was referred to our clinic after lack of response to therapy on imaging. Laboratory evaluation redemonstrated a normal serum IgG4 concentration and fungal studies were consistent with previous histoplasma infection, suggesting fibrosing mediastinitis secondary to histoplasmosis. IgG4-related disease was determined to be unlikely considering repeatedly normal IgG4 levels and weakly positive IgG4 staining. Repeat CT chest demonstrated fibrosis of the left upper lobe; compression of the left atrial appendage; and occlusion and severe obstruction of the left superior pulmonary vein and left lower lobe pulmonary artery, respectively. VQ scan demonstrated significantly reduced perfusion of the left lung and the patient was referred for stenting of the affected vasculature. PET-CT revealed moderate FDG avidity of the left hilar nodes, concerning for ongoing active fibrosing mediastinitis, for which he was continued on rituximab. The indolent nature of fibrosing mediastinitis often leads to advanced disease at the time of presentation. Hilar structures are commonly involved, as in the case of this patient with a severe perfusion defect secondary to obstruction of the pulmonary vessels. A diagnosis of fibrosing mediastinitis merits careful investigation of the underlying cause. Fungal infections, specifically histoplasmosis in North America, are a leading cause of this condition. IgG4-related disease is also associated with fibrosing mediastinitis, and both conditions are driven by fibroinflammatory processes. However, it is important to note that IgG4 immunostaining is non-specific, and diagnosis of IgG4-related disease requires the meeting of rigorous criteria. Differentiation between these diagnoses is important given potential differences in management.
A Case of Refractory, Forme Fruste Non-severe Eosinophilic Granulomatosis With Polyangiitis
Karanam, V., Chetram, Deandra , Kumar, N.R.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5945-A5945

10.1164/ajrccm.2025.211.abstracts.a5945 Get It

Abstract Introduction EGPA is diagnosed clinically in patients with asthma, rhinosinusitis, and eosinophilia with end-organ involvement including neuropathy, lung infiltrates, cardiomyopathy, or kidney, gastrointestinal, or skin involvement. The five-factor score (FFS) differentiates non-severe (FFS = 0) and severe (FFS &gt; 0) EGPA. Forme fruste, or partially treated, EGPA occurs when presumed severe eosinophilic asthma is treated with corticosteroids that can mask end organ damage typical of EGPA. We present a case of forme fruste non-severe EGPA that failed established treatments for non-severe and severe EGPA. Case Presentation This is a 38-year-old female presenting to the pulmonology clinic with three years of cough, dyspnea, wheezing, rhinorrhea, and chest heaviness. She was initially given prednisone for adult-onset asthma with improvement but was unable to taper due to symptom recrudescence on doses lower than 20 milligrams. Allergic bronchopulmonary aspergillosis testing was negative, fractional exhaled nitric oxide was elevated, pulmonary function testing showed moderate airway obstruction, and absolute eosinophil count was 11x10^3/microliter despite prednisone use. Chest computed tomography (CT) showed mild bronchial wall thickening. She was given benralizumab followed by mepolizumab, inhaled corticosteroid with a long-acting beta agonist, cetirizine, nasal budesonide, and two cycles of rituximab for possible EGPA at an outside hospital. At the current evaluation, Chest CT showed multiple nodules, patchy ground glass opacities, and bronchial wall thickening. CT sinuses showed paranasal sinus mucosal thickening with sinus outlet obstruction and nasal endoscopy showed polyps. Anti-neutrophil cytoplasmic antibody was negative, urinalysis showed mild hematuria, and bronchoalveolar lavage was negative for infection. Bone marrow did not suggest neoplasm and hematology workup did not identify other causes of hypereosinophilia. EGPA was considered highest on the differential. She was offered sinus surgery and lung biopsy for enrollment in refractory EGPA trials, but no further medical therapy was identified. Discussion This case shows the importance of recognizing potential forme fruste EGPA rather than asthma refractory to systemic glucocorticoids. Early suspicion is crucial to initiation of the proper regimen. Non-severe EGPA warrants treatment with corticosteroids and mepolizumab. Azathioprine and cyclophosphamide have demonstrated a comparable benefit in relapsing non-severe EGPA after steroid treatment, but in a single low power study. In our patient, who was refractory to glucocorticoids with mepolizumab and rituximab, there is no strong data suggesting further treatment not involving high dose steroids. In her case, chronic steroid use led to morbid obesity and obstructive sleep apnea, highlighting the importance of further research in non-severe EGPA treatment.